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elevated BNP was defined as a concentration above the upper 95th percentile of a nor-
mal range established from a local healthy population.
RESULTS: Of the 147 patients who had clinical evidence of heart failure and both TTE
and BNP results were available, 62% had preserved LV systolic function. 62% of this
group were female (mean age 75 years). The median (range) BNP in patients with
reduced LV systolic function was 589 pg/ml (12-3117) compared to 190 pg/ml (1-2785) in
patients with preserved LV systolic function (p<0.0001). 71% of patients with preserved
LV systolic function had an elevated plasma BNP concentration. However, 43% of this
group also had valve disease or atrial fibrillation. Overall, 41% of patients with clinical
heart failure and preserved LV systolic function had an elevated plasma BNP concentra-
tion and no valve disease or atrial fibrillation.
CONCLUSION: Of all the patients fulfilling standard diagnostic criteria for heart failure
and who had preserved LV systolic function, 41% had biochemical evidence of LV com-
promise and did not have valve disease or atrial fibrillation.
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887-4 Patients With the Metabolic Syndrome Have a High 
Prevalence of Left Ventricular Diastolic Dysfunction
Sheng-Jing Dong, Lisa de las Fuentes, Angela L. Brown, Alan D. Waggoner, Sharon L. 
Heuerman, Robert J. Gropler, Victor G. Davila-Roman, Washington University, St Louis, 
MO
Background: Previous studies have shown the utility of transmitral pulse-wave Doppler-
derived (PWD) indices for the detection of left ventricular diastolic dysfunction. Tissue
Doppler imaging (TDI) is a relatively load-independent method used to assess abnormal
LV relaxation. The prevalence of diastolic dysfunction in the metabolic syndrome has not
been well evaluated.
Methods: 94 subjects were evaluated for variables of metabolic syndrome: 1) waist cir-
cumference > 102 cm in men or > 88 cm in women; 2) triglycerides > 150 mg/dl; 3) HDL
< 40 mg/dl in men or < 50 mg/dl in women; 4) diabetes or fasting blood glucose > 110
mg/dl; 5) history of hypertension or BP > 130/85. 22 subjects (age:43±9, 59% female)
met none (Group 1), 53 (age:48±14, 47% female) met 1-2 (Group 2) and 19 (age:59±8,
51% female) met > 3 criteria of metabolic syndrome (Group 3). Echocardiographic exam-
ination included measurements of ejection fraction (LVEF), LV mass index (LVMI), PWD
transmitral early and late filling velocities (E and A), deceleration time (DT) and TDI-
derived early myocardial velocity at the septal mitral annulus (Em). Based on PWD, nor-
mal diastolic filling (NF) was defined as E/A> 1 and DT = 170-230 ms; impaired relax-
ation (IR) as E/A < 1 and DT > 230 ms; pseudonormalized filling (PN) as E/A > 1 and DT
< 170 ms; and restrictive filling (RF) as E/A > 2 and DT < 170 ms. A TDI-derived Em < 8
cm/s identified abnormal relaxation.
Results: All subjects had normal EF (64 ± 8%). 26 subjects had LVH: 4 (19%) in Group
1, 13 (25%) in Group 2 and 9 (47%) in Group 3. Among subjects unclassifiable by PWD
criteria (n = 21, 22%), TDI allowed reclassification of 16 patients as NF and 5 as IR.
Among those with discordant classification (n = 19, 20%), 3 patients identified as NF by
PWD had IR by TDI, and 16 patients with abnormal diastolic filling [IR (4 patients), PN (7
patients) or RF (5 patients)] by PWD were normal by TDI. Using TDI criteria, the preva-
lence of diastolic dysfunction was 5% in Group 1, 21% in Group 2 and 37% in Group 3.
Conclusions: Patients with metabolic syndrome have a high prevalence of abnormalities
in LV diastolic function. This finding may have important implications in long-term cardio-
vascular morbidity and mortality.
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887-5 Diastolic Heart Failure in Patients Hospitalized With 
Symptomatic Cerebral and Peripheral Vascular Disease
Robert V. Kelly, Esq., Walter Tan, E Magnus Ohman, Allan D. Struthers, University of 
North Carolina, Chapel Hill, NC, University of Dundee, Dundee, Scotland, United 
Kingdom
Background: Patients with Stroke, TIA and claudication are at an increased risk for mor-
bidity and mortality from systolic heart failure (CHF) and ischaemic heart disease. We
have previously reported five times more CHF in these patients compared with the gen-
eral population. Heart failure with preserved LV function/ diastolic heart failure (DHF) is
associated with increased morbidity and hospitalizations in the general population at a
rate similar to that seen in CHF. However, the prevalence of diastolic heart failure (DHF)
in patients presenting with acute cerebral and peripheral vascular syndromes is
unknown.
Methods: Two hundred and twenty-one prospective consecutive patients presenting with
their first stroke, TIA or new onset of claudication underwent history, exam, ECG and
echocardiography. Diastolic heart failure (DHF) was defined as EF>45% + Framingham
signs and symptoms of heart failure. Asymptomatic LV systolic dysfunction (aLVSD) was
defined as an EF<45%.
Results: 
Conclusions: Diastolic heart failure is found in 15% of patients who present to hospital 
with acute vascular syndromes. It is equal in prevalence to systolic HF. Therefore, close 
to two-thirds of patients with symptomatic vascular disease have co-morbid heart failure 
Patients with DHF tend to have a higher prevalence of PVD and less symptomatic cere-
brovascular events compared with CHF patients despite being older and with more 
hypertension, diabetes and atrial fibrillation.
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887-6 Treatment With Inhibitors of Angiontensin-Converting 
Enzyme Improves the Prognosis of Congestive Heart 
Failure With Preserved Systolic Function
Varela Alfonso, Gonzalez-Juanatey Jose Ramón, Grigorian Lilian, Bassante Patricia, 
Barge Eduardo, Pedreira Milagros, Martinez-Sande Luis, Bandín Manuel Angel, García-
Seara Javier, Mazón Pilar, Gil de la Peña Miguel, Hospital Clinico Universitario, Santiago 
de Compostela, Spain
Inhibitors of angiotensin-converting enzyme (ACE) improve the prognosis of congestive
heart failure (CHF) involving systolic dysfunction (SD), but hitherto it has not been known
whether the same is true for CHF without SD. This study compared the effects of ACE
inhibitors on the survival of hospitalized CHF patients with and without SD. Among the
patients hospitalized for CHF in the Cardiology Service of a tertiary hospital between
1991 and 2002, we studied the 958 (aged 69.7
 
±
 
11.7 years) whose left ventricular sys-
tolic function had been evaluated echocardiographically during admission. Of these, 581
(60,6%) were men, 541 (56.5%) had arterial hypertension, 263 (27.5%) were diabetics,
398 (41.5%) were in NYHA class IV, 462(48.2%) had ischaemic cardiopathy (the most
common aetiology), and 610 (63.7%) took ACE inhibitors following admission for CHF.
Ejection fraction was <
 
50% in 572 (59.7%) and >
 
50% in 386 (40.3%). Survival curves
show treatment with ACE inhibitors to have benefited both these groups to a statistically
significant degree.
Conclusion: ACE inhibitors lengthen the lives of CHF patients whether or not they have
systolic dysfunction. 
Clinical variables Normal LV
(n=83)
Diastolic HF
(n=32)
Systolic HF
(n= 34)
aLVSD
(n=72)
Mean age (years)
Female gender (%)
68
52 (63)
71
16 (50)
69
13 (38)
65
24 (33)
Stroke (%)
TIA
PVD
29 (35)
24 (30)
29 (35)
10 (31)
10 (31)
12 (38)
12 (35)
14 (41)
8 (24)
23 (31)
26 (38)
23 (31)
IHD/ MI (%)
Hypertension
Diabetes
Prior CABG
Smokers
Hypercholestrol
6 (7)
46 (55)
8 (10)
0 (0)
68 (82)
10 (31)
15 (47)
20 (63)
5 (16)
5 (16)
27 (84)
10 (31)
18 (53)
16 (47)
4 (12)
7 (21)
29 (86)
17 (50)
20 (28)
27 (38)
9 (13)
8 (11)
50(69)
33 (46)
Atrial fibrillation (%) 6 (7) 4 (13) 3 (8) 10 (14)
